Nomegestrol acetate for symptomatic endometriosis and meningioma risk: understandable statistics for decision-making

The increase in meningioma risk in users of COC containing NOMAC is limited 72 in women aged 20-34 years, even after long periods of use. Because age is the most important risk factor, a maximum of five years of E2/NOMAC combination use in women aged 35-44 and 30 74 months of use in women aged 45-54 years might be considered reasonable thresholds. Considering 75 these thresholds, we can expect respectively one case of meningiomas out of respectively 992 and 76 1923 treated cases.